Grifols | GRFS - Sales Revenues


Grifols reported EUR2B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 2.29M 107.78M Mar/2026
Bio Path 0 0 Mar/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Grifols EUR 2B 306.7M Mar/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Sangamo BioSciences USD 356K 125K Jun/2024
TherapeuticsMD USD 234K 79K Jun/2024